Cargando…

Recent Advances in Nanoplatforms for the Treatment of Osteosarcoma

Osteosarcoma (OS) is the most common primary bone tumor in children and young people. Traditional surgical excision combined with chemotherapy presents many limitations, such as resistance and systemic side effects of chemotherapy drugs, postoperative recurrence, and bone defects. Given these limita...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Kunzhe, Yu, Beibei, Li, Di, Tian, Yangyang, Liu, Yan, Jiang, Jinlan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885548/
https://www.ncbi.nlm.nih.gov/pubmed/35242707
http://dx.doi.org/10.3389/fonc.2022.805978
_version_ 1784660448290799616
author Wu, Kunzhe
Yu, Beibei
Li, Di
Tian, Yangyang
Liu, Yan
Jiang, Jinlan
author_facet Wu, Kunzhe
Yu, Beibei
Li, Di
Tian, Yangyang
Liu, Yan
Jiang, Jinlan
author_sort Wu, Kunzhe
collection PubMed
description Osteosarcoma (OS) is the most common primary bone tumor in children and young people. Traditional surgical excision combined with chemotherapy presents many limitations, such as resistance and systemic side effects of chemotherapy drugs, postoperative recurrence, and bone defects. Given these limitations, novel therapeutic modalities for OS treatment using nanometer-sized platform-based chemotherapeutic delivery have emerged as a promising alternative therapy. This form of therapy offers multiple advantages, such as accurate delivery of the drug to the tumor site and repair of limited bone defects after tumor resection. In this review, we briefly summarize nanoplatforms, including liposomes, polymeric nanoparticles, inorganic nanoparticles, nanomicelles, dendrimers, nanocapsules, and exosomes. The essential shortcomings involved in these nanoplatforms, such as poor stability, immunogenicity, insufficient circulation, and drug leakage are also discussed, and related solutions are briefly proposed. Finally, the application prospects of nanoplatforms in the treatment of OS are discussed.
format Online
Article
Text
id pubmed-8885548
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88855482022-03-02 Recent Advances in Nanoplatforms for the Treatment of Osteosarcoma Wu, Kunzhe Yu, Beibei Li, Di Tian, Yangyang Liu, Yan Jiang, Jinlan Front Oncol Oncology Osteosarcoma (OS) is the most common primary bone tumor in children and young people. Traditional surgical excision combined with chemotherapy presents many limitations, such as resistance and systemic side effects of chemotherapy drugs, postoperative recurrence, and bone defects. Given these limitations, novel therapeutic modalities for OS treatment using nanometer-sized platform-based chemotherapeutic delivery have emerged as a promising alternative therapy. This form of therapy offers multiple advantages, such as accurate delivery of the drug to the tumor site and repair of limited bone defects after tumor resection. In this review, we briefly summarize nanoplatforms, including liposomes, polymeric nanoparticles, inorganic nanoparticles, nanomicelles, dendrimers, nanocapsules, and exosomes. The essential shortcomings involved in these nanoplatforms, such as poor stability, immunogenicity, insufficient circulation, and drug leakage are also discussed, and related solutions are briefly proposed. Finally, the application prospects of nanoplatforms in the treatment of OS are discussed. Frontiers Media S.A. 2022-02-15 /pmc/articles/PMC8885548/ /pubmed/35242707 http://dx.doi.org/10.3389/fonc.2022.805978 Text en Copyright © 2022 Wu, Yu, Li, Tian, Liu and Jiang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wu, Kunzhe
Yu, Beibei
Li, Di
Tian, Yangyang
Liu, Yan
Jiang, Jinlan
Recent Advances in Nanoplatforms for the Treatment of Osteosarcoma
title Recent Advances in Nanoplatforms for the Treatment of Osteosarcoma
title_full Recent Advances in Nanoplatforms for the Treatment of Osteosarcoma
title_fullStr Recent Advances in Nanoplatforms for the Treatment of Osteosarcoma
title_full_unstemmed Recent Advances in Nanoplatforms for the Treatment of Osteosarcoma
title_short Recent Advances in Nanoplatforms for the Treatment of Osteosarcoma
title_sort recent advances in nanoplatforms for the treatment of osteosarcoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885548/
https://www.ncbi.nlm.nih.gov/pubmed/35242707
http://dx.doi.org/10.3389/fonc.2022.805978
work_keys_str_mv AT wukunzhe recentadvancesinnanoplatformsforthetreatmentofosteosarcoma
AT yubeibei recentadvancesinnanoplatformsforthetreatmentofosteosarcoma
AT lidi recentadvancesinnanoplatformsforthetreatmentofosteosarcoma
AT tianyangyang recentadvancesinnanoplatformsforthetreatmentofosteosarcoma
AT liuyan recentadvancesinnanoplatformsforthetreatmentofosteosarcoma
AT jiangjinlan recentadvancesinnanoplatformsforthetreatmentofosteosarcoma